Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 14.9% in February

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 3,940,000 shares, a drop of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily trading volume, of 895,400 shares, the days-to-cover ratio is currently 4.4 days. Currently, 7.1% of the shares of the stock are short sold.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company's stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.93% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. State Street Corp raised its position in shares of Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after acquiring an additional 216,484 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $33,767,000. BNP Paribas Financial Markets lifted its stake in Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 1,570 shares during the last quarter. FMR LLC lifted its stake in Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after purchasing an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Agios Pharmaceuticals in the third quarter valued at approximately $892,000.

Remove Ads

Analysts Set New Price Targets

AGIO has been the topic of a number of recent analyst reports. Scotiabank raised their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Royal Bank of Canada lifted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $56.57.

Agios Pharmaceuticals Stock Down 4.3 %

Shares of Agios Pharmaceuticals stock traded down $1.41 on Friday, hitting $31.30. The stock had a trading volume of 1,667,710 shares, compared to its average volume of 683,804. Agios Pharmaceuticals has a twelve month low of $27.14 and a twelve month high of $62.58. The business's 50 day moving average is $33.38 and its two-hundred day moving average is $41.31. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of 2.76 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.